USA flag logo/image

An Official Website of the United States Government

SBIR Phase I: Humanized Mouse Ig system employing BAC

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
88218
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
0739548
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Aliva Biopharmaceuticals
11 West Del Mar Boulevard, Suite 202 Pasadena, CA 91105 2505
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: SBIR Phase I: Humanized Mouse Ig system employing BAC
Agency: NSF
Contract: 0739548
Award Amount: $100,000.00
 

Abstract:

This Small Business Innovation Research (SBIR) Phase I research project aims to introduce the entire human immunoglobulin locus into the mouse in order to enable the subsequent production of completely humanized monoclonal antibodies from hybridomas. Monoclonal antibodies against cell surface proteins are currently being used for a variety of clinical indications, including cancer and autoimmunity. Their binding avidity and specificity make them one of the most important modes of therapy for the treatment of a variety of diseases where specific targeting is required. The current technology is based on a system where only 80% of the immunoglobulin locus has been humanized. Replacement of the remaining mouse genes with the human ones will improve the quality and diversity of the antibodies produced and as such, will be an important contribution to this important therapeutic modality.

Principal Investigator:

Hiroaki Shizuya
PhD
6266839812
shizuya@alivabio.com

Business Contact:

Hiroaki Shizuya
PhD
6266839812
shizuya@alivabio.com
Small Business Information at Submission:

Aliva Biopharmaceuticals
11 West Del Mar Boulevard, Suite 202 Pasadena, CA 91105

EIN/Tax ID: 954866757
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No